Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04763564 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Liraglutide Therapy in Patients With IPAA
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04763564 is a Phase 2 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 8 participants.
The verdict
NCT04763564, a Phase 2 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Patients with an ileal pouch-anal anastomosis(IPAA; pouch) due to refractory inflammatory bowel disease and increased bowel frequency in the absence of significant pouch inflammation will be randomized to liraglutide or placebo in a prospective cross over study.
Interventions
- DRUG Liraglutide Pen Injector
- DRUG Placebo Pen Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04763564
The ClinicalTrials.gov registry entry for NCT04763564 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liraglutide Pen Injector is the first listed.
NCT04763564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04763564 about?
NCT04763564 is a clinical study titled "Efficacy of Liraglutide Therapy in Patients With IPAA". Patients with an ileal pouch-anal anastomosis(IPAA; pouch) due to refractory inflammatory bowel disease and increased bowel frequency in the absence of significant pouch inflammation will be randomized to liraglutide or placebo in a prospective cross over study.
What is the current status of trial NCT04763564?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-03-22. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT04763564?
The interventions under investigation include: Liraglutide Pen Injector (DRUG), Placebo Pen Injector (DRUG).
Who is sponsoring clinical trial NCT04763564?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.